Education
About Us
Working with TipRanks
Follow Us
Biophytis (BPTSY)
OTHER OTC:BPTSY
Top Page
Biophytis
(OTC:BPTSY)
Select Model
Select Model
Rating:35Underperform
Price Target:―
Biophytis faces significant financial challenges, with ongoing losses and negative equity posing major risks. While there is some short-term technical strength, the long-term technical indicators and valuation metrics highlight weaknesses. The lack of substantial earnings call information increases uncertainty, contributing to a low overall score.
Biophytis (BPTSY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.57M
Dividend YieldN/A
Average Volume (3M)0.00
Price to Earnings (P/E)―
Beta (1Y)0.58
Revenue GrowthN/A
EPS Growth82.47%
CountryUS
Employees22
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,343,177
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap2.24
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-7.84
Enterprise Value/Ebitda-0.88
Forecast
1Y Price Target
$15.00Price Target Upside669.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Biophytis Business Overview & Revenue Model
Company DescriptionBiophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics targets and activates key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is BIO101, an orally administered small molecule in development to treat neuromuscular diseases, including sarcopenia, Duchenne muscular dystrophy (DMD), and obesity, as well as treatment of severe respiratory failure in patients suffering from COVID-19. It also develops BIO201, an orally administered small molecule for the treatment of retinopathies, including dry age-related macular degeneration, and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.
How the Company Makes MoneyBiophytis generates revenue through the development and potential commercialization of its drug candidates. The company's revenue model primarily focuses on licensing agreements, partnerships, and collaborations with other pharmaceutical companies, which may involve upfront payments, milestone payments, and royalties based on product sales. Additionally, Biophytis may receive funding from grants and research collaborations to support its clinical trials and research initiatives. The success of its revenue model is contingent upon the progression and approval of its drug candidates through clinical trials and regulatory processes.
Biophytis Financial Statement Overview
Summary
Biophytis is experiencing significant financial distress characterized by continuous operating losses, negative equity, and reliance on external financing. The absence of revenue poses a major challenge, while the ongoing cash burn and high debt levels present substantial risks to financial stability.Income Statement
Biophytis has faced consistent financial challenges with no revenue generation over the past years. The company has significant negative EBIT and EBITDA margins due to high operating losses. Net profit margins remain deeply negative, reflecting the ongoing unprofitability.20
Very Negative
Balance Sheet
The balance sheet reveals significant financial instability with negative stockholders' equity, indicating a concerning level of leverage. The debt-to-equity ratio cannot be calculated due to negative equity, and the company relies heavily on debt financing. Total liabilities exceed total assets, further highlighting financial vulnerability.15
Very Negative
Cash Flow
Cash flow analysis shows negative operating and free cash flows, indicating poor cash generation capabilities. However, a reduction in negative free cash flow over time suggests some improvements in cash management. The company is heavily reliant on financing activities for cash inflow.30
Negative
| Breakdown | TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.31M | -803.00K | -484.00K | -311.00K | -280.00K | -262.00K |
| EBITDA | -11.66M | -13.80M | -23.04M | -26.50M | -13.66M | -15.42M |
| Net Income | -15.07M | -17.03M | -24.22M | -31.16M | -25.52M | -18.95M |
Balance Sheet | ||||||
| Total Assets | 8.71M | 11.96M | 21.99M | 36.26M | 27.21M | 17.67M |
| Cash, Cash Equivalents and Short-Term Investments | 2.19M | 5.57M | 11.64M | 25.16M | 18.77M | 6.81M |
| Total Debt | 9.71M | 8.27M | 12.13M | 15.38M | 9.10M | 15.24M |
| Total Liabilities | 15.13M | 15.85M | 23.90M | 30.56M | 20.38M | 25.20M |
| Stockholders Equity | -6.38M | -3.86M | -1.88M | 5.74M | 6.86M | -7.50M |
Cash Flow | ||||||
| Free Cash Flow | -10.80K | -13.09M | -19.13M | -24.14M | -10.08M | -15.55M |
| Operating Cash Flow | -10.66K | -12.87M | -18.99M | -23.80M | -9.86M | -15.27M |
| Investing Cash Flow | 1.14K | 370.00K | -17.00K | 12.16M | -12.71M | -278.00K |
| Financing Cash Flow | 5.92K | 7.03M | 6.13M | 29.71M | 22.07M | 7.50M |
Biophytis Technical Analysis
Negative
1.95
Price Trends
1.96
Negative
1.79
Positive
2.42
Negative
Market Momentum
>-0.01
Positive
47.82
Neutral
54.62
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BPTSY, the sentiment is Negative. The current price of 1.95 is below the 20-day moving average (MA) of 2.00, below the 50-day MA of 1.96, and below the 200-day MA of 2.42, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 47.82 is Neutral, neither overbought nor oversold. The STOCH value of 54.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BPTSY.
Biophytis Risk Analysis
Biophytis disclosed 71 risk factors in its most recent earnings report. Biophytis reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
Our drug candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval or authorization, limit the commercial profile of an approved or authorized label, or result in significant negative consequences following marketing approval or authorization, if any. Q4, 2023
2.
A resurgence of COVID-19 (or emergence of new vaccine resistant strains), pandemic, endemic, or emergence of other infectious disease, may limit our ability or the investigators' ability to find and retain medical staffs that are needed to conduct the clinical studies. Q4, 2023
Biophytis Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | 622.78M | 6.41 | 119.39% | ― | 105.62% | 0.00% | |
71 Outperform | 2.62B | 861.80 | 0.97% | ― | 56.18% | 0.00% | |
68 Neutral | 9.12B | -102.91 | 0.00% | ― | 0.00% | 34.29% | |
44 Neutral | 26.50M | ― | 0.00% | ― | 0.00% | 0.00% | |
35 Underperform | $4.57M | ― | 441.43% | ― | ― | 82.47% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
BPTSY
Biophytis
1.95
-2.90
-59.79%
TCRT
Alaunos Therapeutics
2.42
-0.70
-22.44%
SONN
Sonnet BioTherapeutics Holdings
6.20
-1.35
-17.88%
WINT
Windtree Therapeutics
0.08
-171.42
-99.95%
MBIO
Mustang Bio
1.67
-8.99
-84.33%
AEON
AEON Biopharma
0.76
-48.86
-98.47%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.